Suppr超能文献

[血脂异常(II型和IV型)患者的胆汁脂质成分。一种新型降血脂药物(益多酯)的作用]

[Bile lipid composition in subjects with blood lipid disorders (types II and IV). Effect of a new hypolipemic drug (Etofibrate)].

作者信息

Altomonte L, Mingrone G, Ghirlanda G, Manna R, Rebuzzi A, Pala M A, Greco A V

出版信息

Minerva Med. 1980 Feb 11;71(4):273-8.

PMID:7354946
Abstract

The biliary lithogenous index before and after treatment with Etofibrate, a new hypolipaemizing substance, has been assessed in dyslipidaemic subjects (ypes II and IV). Etofibrate is the result of the association of a molecule of clofibrate and one of nicotinic acid. An analysis of relative molar concentrations of biliary lipides showed that subjects with type IV and IIb dyslipidaemia produced lithogenous bile in base condition, unlike subjects with type IIa dyslipidaemia. After 28 days of treatment with Etofibrate (900 mg/die) a clear-cut increase was observed in the biliary lithogenous index in all types of dyslipidaemia examined.

摘要

已在血脂异常患者(II型和IV型)中评估了新型降血脂物质益多酯治疗前后的胆汁致石指数。益多酯是氯贝丁酯分子与烟酸分子结合的产物。胆汁脂质相对摩尔浓度分析表明,与IIa型血脂异常患者不同,IV型和IIb型血脂异常患者在基础状态下会产生致石性胆汁。在用益多酯(900毫克/日)治疗28天后,在所有检查的血脂异常类型中,胆汁致石指数均出现明显升高。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验